Drug repositioning in neurodegeneration: An overview of the use of ambroxol in neurodegenerative diseases.
Fiche publication
Date publication
juillet 2020
Journal
European journal of pharmacology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr LOEFFLER Jean-Philippe
Tous les auteurs :
Bouscary A, Quessada C, René F, Spedding M, Henriques A, Ngo S, Loeffler JP
Lien Pubmed
Résumé
Amyotrophic lateral sclerosis (ALS) is the most common motor neuron disease in adults. While it is primarily characterized by the death of upper and lower motor neurons, there is a significant metabolic component involved in the progression of the disease. Two-thirds of ALS patients have metabolic alterations that are associated with the severity of symptoms. In ALS, as in other neurodegenerative diseases, the metabolism of glycosphingolipids, a class of complex lipids, is strongly dysregulated. We therefore assume that this pathway constitutes an interesting avenue for therapeutic approaches. We have shown that the glucosylceramide degrading enzyme, glucocerebrosidase (GBA) 2 is abnormally increased in the spinal cord of the SOD1 mouse model of ALS. Ambroxol, a chaperone molecule that inhibits GBA2, has been shown to have beneficial effects by slowing the development of the disease in SOD1 mice. Currently used in clinical trials for Parkinson's and Gaucher disease, ambroxol could be considered as a promising therapeutic treatment for ALS.
Mots clés
ALS, Ambroxol, GBA2, Glucosylceramide, Neurodegenerative disease
Référence
Eur. J. Pharmacol.. 2020 Jul 30;:173446